Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01329965 · ClinicalTrials.gov registry record · Phase 1
Safety and Feasibility of an Endotoxemia Model
A Phase 1 study, sponsored by Penn State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01329965: Completed Phase 1 study, sponsored by Penn State University.
NCT01329965 is a Phase 1 study that has completed, run by Penn State University. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01329965, a Phase 1 study, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety and feasibility of low dose LPS administration to a small subset of humans in preparation for a larger USDA funded study examining what is the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response the investigators wish to examine the effects of an endotoxemia model for inducing inflammation. Based on previous research, low dose LPS administration affects metabolism in humans with only minimal clinical effects (such as "flu" like illness). Therefore, each of the six subjects included in this small pilot study will receive a low dose of LPS and placebo in order to learn more about the metabolic changes that occur during administration and inflammation. The investigators hypothesis that LPS administration will elicit only minimal clinical effects (such as "flu" like illness) when compared to placebo (saline--water with the same amount of salt as in your blood).
Interventions
- DRUG LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
What the finished NCT01329965 record still lists
NCT01329965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP) is the first listed.
NCT01329965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01329965 about?
NCT01329965 is a clinical study titled "Safety and Feasibility of an Endotoxemia Model". The purpose of this study is to establish the safety and feasibility of low dose LPS administration to a small subset of humans in preparation for a larger USDA funded study examining what is the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) th...
What is the current status of trial NCT01329965?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-04. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01329965?
The interventions under investigation include: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP) (DRUG).
Who is sponsoring clinical trial NCT01329965?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01329965's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia